Vaxcyte, Inc. (PCVX) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Vaxcyte, Inc.
Address
825 Industrial Road
San Carlos, CA 94070
United States of America (the)
Phone
650 837 0111
Website
Sector
Healthcare
Industry
Biotechnology
Employees
414
First IPO Date
June 12, 2020
Key Executives
| Name | Title | Pay | Year Born |
| Grant E. Pickering | Co-Founder, Chief Executive Officer & Director | 1.44M | 1968 |
| James Wassil | Executive Vice President & Chief Operating Officer | 614,730 | 1969 |
| Harp Dhaliwal | Chief Technical Operations Officer | 743,618 | 1973 |
| Mikhail Eydelman | Senior Vice President, General Counsel, Chief Compliance Officer & Corporate Secretary | 752,712 | 1982 |
| Andrew L. Guggenhime | President & Chief Financial Officer | 960,230 | 1968 |
| Whitney Jones | Chief People Officer | 0 | N/A |
| Chris Griffith | Chief Business & Strategy Officer | 0 | N/A |
| Elvia Cowan | Senior VP of Finance & Chief Accounting Officer | 0 | 1973 |
| Janet Graesser | Senior Vice President of Corporate Affairs | 0 | N/A |
| Jeff Fairman | Co-Founder & Vice President of Research | 0 | 1964 |
| Jeff Macdonald | Executive Director of Investor Relations | 0 | N/A |
| Mike Mullette | Chief Commercial Officer | 0 | N/A |
| Sam Iki | Senior Vice President of Project Management | 0 | N/A |
Description
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
